Praxis Precision Medicines, Inc. (PRAX)
Nasdaq · Healthcare · Biotechnology
$283.56−4.04%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $7.9B
- 52-week range
- $50.31 – $392.70
- 52-week change
- +479.66%
- EPS (trailing)
- −$12.95
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$303M
- Diluted EPS
- −$13.48
- Free cash flow
- −$249M
From the company’s annual report on SEC EDGAR.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE.
Headquarters: Boston, United States · 168 employees · praxismedicines.com